Alpha Tau Medical Ltd. (DRTS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2025-12-31..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2025-12-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 32.06M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 10.62M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -42.29M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $32.06M | (m) | $10.62M | $-42.29M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $27.89M | (m) | $10.38M | $-37.52M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $27.02M | (m) | $9.92M | $-36.04M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $27.48M | (m) | $9.01M | $-36.35M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $26.42M | (m) | $7.93M | $-35.68M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $22.47M | (m) | $7.09M | $-32.16M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $20.89M | (m) | $6.75M | $-32.14M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $11.45M | (m) | $812.00K | $13.79M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $7.54M | (m) | $596.00K | $9.24M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $6.64M | (m) | $546.00K | $8.01M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.